• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
Menu
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

BI announces new data from Stiolto/Spiolto Respimat studies

Boehringer Ingelheim has announced new data from the ENERGITO and OTEMTO studies of the Stiolto tiotropium/olodaterol Respimat inhaler for the treatment of COPD. The FDA approved Stiolto Respimat in May 2015; in Europe, where the product is known as Spiolto Respimat, BI announced approval by several countries in July 2015. BI previously announced data from OTEMTO 1&2 showing that Stiolto Respimat improves quality of life.

The new data from ENERGITO show increased FEV1 AUC0–12, the primary endpoint, for moderate-to-severe COPD patients using once-daily Stiolto Respimat for six weeks compared to a fluticasone/salmeterol DPI twice daily.

Boehringer Ingelheim VP, Clinical Development & Medical Affairs, Respiratory, Danny McBryan said, “As a leader in COPD care for more than 40 years in the US, we’re encouraged by these new data that further our knowledge of the potential benefits of Stiolto Respimat. Based on the available clinical data, we believe Stiolto Respimat will help address unmet patient needs in the COPD community.”

Read the Boehringer Ingelheim press release.

Share

published on September 28, 2015

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews